ASKA Pharmaceutical Holdings Co.,Ltd.
TSE:4886.T
2187 (JPY) • At close November 5, 2024
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) JPY.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Omzet
| 62,843 | 60,461 | 56,607 | 55,181 | 52,542 | 46,705 | 48,944 | 48,527 | 43,215 | 42,907 | 39,501 | 40,963 |
Kosten van de omzet
| 32,178 | 31,876 | 30,255 | 29,798 | 28,525 | 27,814 | 30,059 | 29,614 | 26,072 | 25,714 | 22,431 | 23,054 |
Brutowinst
| 30,665 | 28,585 | 26,352 | 25,383 | 24,017 | 18,891 | 18,885 | 18,913 | 17,143 | 17,193 | 17,070 | 17,909 |
Brutowinstmarge
| 0.488 | 0.473 | 0.466 | 0.46 | 0.457 | 0.404 | 0.386 | 0.39 | 0.397 | 0.401 | 0.432 | 0.437 |
Onderzoek- en ontwikkelingskosten
| 4,728 | 4,227 | 3,598 | 0 | 4,913 | 4,493 | 4,055 | 4,970 | 4,174 | 4,025 | 4,144 | 4,269 |
Algemene en administratieve kosten
| 13,131 | 13,161 | 12,191 | 0 | 11,603 | 11,729 | 11,042 | 11,136 | 10,783 | 10,692 | 11,111 | 11,323 |
Verkoop- en marketingkosten
| 6,305 | 6,088 | 5,767 | 0 | 5,993 | 885 | 963 | 1,013 | 1,021 | 1,050 | 1,098 | 1,255 |
Verkoop-, algemene en administratieve kosten
| 19,436 | 19,249 | 17,958 | 21,773 | 17,596 | 12,614 | 12,005 | 12,149 | 11,804 | 11,742 | 12,209 | 12,578 |
Overige kosten
| -165 | -67 | -73 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Bedrijfskosten
| 24,164 | 23,476 | 21,556 | 21,773 | 22,509 | 17,107 | 16,060 | 17,119 | 15,977 | 15,655 | 16,275 | 16,424 |
Bedrijfsresultaat
| 6,501 | 5,108 | 4,795 | 3,610 | 1,508 | 1,784 | 2,825 | 1,794 | 1,166 | 1,411 | 702 | 1,047 |
Bedrijfsresultaat ratio
| 0.103 | 0.084 | 0.085 | 0.065 | 0.029 | 0.038 | 0.058 | 0.037 | 0.027 | 0.033 | 0.018 | 0.026 |
Totaal overige inkomsten en kosten netto
| 3,361 | 247 | 1,368 | -35 | -607 | 99 | 238 | 1,506 | 282 | 277 | 244 | 545 |
Inkomen voor belasting
| 9,862 | 5,357 | 6,163 | 3,575 | 901 | 1,883 | 3,063 | 3,300 | 1,448 | 1,688 | 946 | 1,592 |
Inkomen voor belasting ratio
| 0.157 | 0.089 | 0.109 | 0.065 | 0.017 | 0.04 | 0.063 | 0.068 | 0.034 | 0.039 | 0.024 | 0.039 |
Belastingkosten
| 2,316 | 1,118 | 1,873 | 861 | 252 | 138 | 674 | 356 | 747 | 530 | 421 | 482 |
Nettowinst
| 7,545 | 4,238 | 4,290 | 2,713 | 649 | 1,744 | 2,388 | 2,944 | 701 | 1,193 | 495 | 1,114 |
Nettowinstmarge
| 0.12 | 0.07 | 0.076 | 0.049 | 0.012 | 0.037 | 0.049 | 0.061 | 0.016 | 0.028 | 0.013 | 0.027 |
WPA (Winst Per Aandeel)
| 266.49 | 150.08 | 151.22 | 95.63 | 22.94 | 61.8 | 84.77 | 105.37 | 25.14 | 42.86 | 17.82 | 40.27 |
Verwaterde WPA
| 266.49 | 150.08 | 151.22 | 95.63 | 22.94 | 61.8 | 84.77 | 105.37 | 25.14 | 42.86 | 17.82 | 40.27 |
EBITDA
| 9,163 | 8,462 | 7,863 | 6,972 | 5,269 | 4,402 | 5,219 | 4,295 | 3,223 | 3,226 | 3,161 | 3,481 |
EBITDA ratio
| 0.146 | 0.14 | 0.139 | 0.126 | 0.1 | 0.094 | 0.107 | 0.089 | 0.075 | 0.075 | 0.08 | 0.085 |